China NMPA Product Recall - Ureteral stent

On August 5, 2021, the National Medical Products Administration (NMPA) announced a voluntary Class III recall initiated by Boston Scientific International Medical Trading (Shanghai) Co., Ltd. The recall pertains to specific batches of ureteral stents. The company reported that these medical devices were found to be non-compliant with certain Product Technical Requirements (PTRs), particularly concerning fixation strength. However, Boston Scientific's subsequent investigation determined that the non-compliance was solely attributed to a textual error within the PTR document itself. Crucially, the company affirmed that the recalled ureteral stents fully conform to Boston Scientific's established design and performance specifications. As a result, no adverse health consequences or patient risks are expected from the use of these products. Despite the absence of direct patient harm, Boston Scientific proactively initiated a voluntary recall to address this documentation discrepancy, operating under the regulatory oversight of the NMPA and Shanghai Municipal Drug Administration. This demonstrates the company's commitment to maintaining rigorous product quality standards and ensuring compliance with regulatory frameworks, even in cases where the issue is administrative rather than a functional defect.